Adaptimmune continues upward trajectory with Astellas allogeneic cell therapy deal

Adaptimmune continued its run of J.P. Morgan news Tuesday, announcing a discovery partnership with Japanese pharma Astellas to develop allogeneic T cell therapies for cancer.

The announcement follows a 200% gain for Adaptimmune Therapeutics plc (NASDAQ:ADAP) Monday after the company reported updated data showing initial responses to its SPEAR T cell therapies across four different solid tumor indications (see “Adaptimmune Rises on Early Promise for SPEAR TCR Cell Therapies in Solid Tumors”)...